Vertex Pharmaceuticals Incorporated
Organization details
- Legal name
- Vertex Pharmaceuticals Incorporated
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Massachusetts
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- VRTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000875320
- EIN
- 04-3039129
- Wikidata ID
- Q2744099
Board of directors
-
Alan M. Garber · DirectorSince 2023
-
Bruce I. Sachs · DirectorSince 2023
-
Daniel J. Brennan · DirectorSince 2026
-
Diana Mckenzie · DirectorSince 2023
-
Jeffrey M. Leiden · Director · Executive ChairmanSince 2023
-
Jennifer Schneider · DirectorSince 2024
-
Lloyd Carney · DirectorSince 2023
-
Margaret G. Mcglynn · DirectorSince 2023
-
Michel Lagarde · DirectorSince 2023
-
Nancy Thornberry · DirectorSince 2023
-
Reshma Kewalramani · Director · CEO & PresidentSince 2023
-
Sangeeta N. Bhatia · DirectorSince 2023
-
Suketu Upadhyay · DirectorSince 2023
-
Terrence C. Kearney · DirectorSince 2023
-
Yuchun Lee · DirectorSince 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 99
- Earnings growth 15%
- 97
19.3% a year in revenue
22.6% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2019 – December 2025.
Director election results
Annual meeting of May 13, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.1%
-
95.6%
-
98.4%
-
98.8%
-
98.8%
-
98.9%
-
99.3%
-
99.3%
-
99.3%
-
99.6%
Board connections
9 of this board's directors also sit on 13 other boards. 9 are in the same sector.
-
Denali Therapeutics Inc. Same sectorvia Nancy Thornberry
-
Exelixis Inc. Same sectorvia Alan M. Garber
-
Ginkgo Bioworks Holdings Inc. Same sectorvia Reshma Kewalramani
- via Lloyd Carney
-
Madrigal Pharmaceuticals Inc. Same sectorvia Daniel J. Brennan
- via Diana Mckenzie
-
Novavax Inc. Same sectorvia Margaret G. Mcglynn
-
Odyssey Therapeutics Inc. Same sectorvia Jeffrey M. Leiden
-
Schrodinger Inc. Same sectorvia Nancy Thornberry
- via Lloyd Carney
- via Daniel J. Brennan
-
West Pharmaceutical Services Inc. Same sectorvia Michel Lagarde
-
agilon health inc. Same sectorvia Diana Mckenzie
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $164,404,637
- 94 sales by 13 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Reshma Kewalramani Director, Officer (CEO & President) | Open-market sale | −11,866 | $531.53 | $6,307,135 |
| Oct 20, 2026 | Daniel J. Brennan Director | Grant or award | +795 | $503.47 | $400,259 |
| Sep 8, 2026 | van Grunsven Jasper Officer (EVP, CP and NPPO) | Grant or award | +8,682 | — | — |
| Aug 28, 2026 | Ambrose Kristen Officer (SVP & Chief Accounting Officer) | Grant or award | +5,000 | — | — |
| Aug 27, 2026 | Bruce I. Sachs Director | Gift | −6,000 | — | — |
| Jul 21, 2026 | Sachdev Amit Officer (EVP Chief Patient & Ext Af Off) | Grant or award | +8,251 | — | — |
| Jul 21, 2026 | Ourania Tatsis Officer (EVP, Chief Reg. & Quality Off.) | Grant or award | +8,251 | — | — |
| Jul 2, 2026 | McKechnie Duncan Officer (EVP, Chief Commercial Officer) | Open-market sale | −1,541 | $519.00 | $799,779 |
| Jul 2, 2026 | Ourania Tatsis Officer (EVP, Chief Reg. & Quality Off.) | Open-market sale | −1,500 | $524.99 | $787,485 |
| Jul 1, 2026 | Liu Joy Officer (EVP and Chief Legal Officer) | Open-market sale | −828 | $502.71 | $416,244 |
| Jun 26, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −596 | $482.50 | $287,570 |
| Jun 18, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −1,020 | $462.17 | $471,413 |
| Jun 15, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −4,062 | $450.00 | $1,827,900 |
| Jun 5, 2026 | Bozic Carmen Officer (EVP and CMO) | Open-market sale | −1,745 | $450.00 | $785,250 |
| Jun 1, 2026 | Liu Joy Officer (EVP and Chief Legal Officer) | Open-market sale | −828 | $439.91 | $364,245 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Vertex Pharmaceuticals Incorporated
Who is the CEO of Vertex Pharmaceuticals Incorporated?
Reshma Kewalramani has been Vertex Pharmaceuticals Incorporated's CEO & President since April 2020.
How many directors are on Vertex Pharmaceuticals Incorporated's board?
Vertex Pharmaceuticals Incorporated's board has 15 directors: Alan M. Garber, Bruce I. Sachs, Daniel J. Brennan, Diana Mckenzie, Jeffrey M. Leiden, Jennifer Schneider, Lloyd Carney, Margaret G. Mcglynn, Michel Lagarde, Nancy Thornberry and 5 others.
Are Vertex Pharmaceuticals Incorporated insiders buying or selling shares?
Over the last 12 months, Vertex Pharmaceuticals Incorporated insiders made no open-market purchases and sold $164.4 million of shares in 94 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="vertex-pharmaceuticals-incorporated"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.